Inflammation and Brain Function - Main Study
Primary Purpose
Sickness Behavior
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Endotoxin
Placebo
Sponsored by
About this trial
This is an interventional basic science trial for Sickness Behavior focused on measuring Sickness behavior, Endotoxin, Lipopolysaccharide, Psychoneuroimmunology
Eligibility Criteria
Inclusion Criteria:
- Healthy subjects
Exclusion Criteria:
- Diagnosed physiological or psychiatric disease
- Needle anxiety or blood phobia
- Regular medication (excluding contraceptive pill)
- Infection in the last two weeks
- Pregnancy or breastfeeding
- Smoking
- Excessive alcohol use
- Body mass index in the range of obesity (>30 kg/m2) or underweight (<18.5 kg/m2)
- Invisible veins in the antecubital area of the arms
- Known or risk of metal inserted in body
- Claustrophobic tendensies
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Endotoxin
Placebo
Arm Description
Endotoxin 0.6 ng/kg body weight injection
Saline injection
Outcomes
Primary Outcome Measures
Pain sensitivity (cutaneous and deep)
Both deep and cutaneous pain at threshold and suprathreshold noxious levels. Heat- and cold (cutaneous) pain sensitivity was assessed for threshold stimuli and intense noxious stimuli, as well as pressure (deep) pain thresholds and CPM (descending pain inhibition).
Brain function
BOLD activity from MR scans
Functional connectivity of the insular cortex during acute inflammation, in relation to symptoms of sickness.
Changes in central pain mechanism during acute inflammation, assessed as activity in the insula and areas of the descending pain inhibitory pathways in the brain.
Changes in brain function during an emotional task with an interoceptive component during acute inflammation.
Secondary Outcome Measures
Self-rated health
"How is your health right now?" rated on a 7 point Likert scale at baseline, after 90 minutes and after 4.5 hours.
"How do you rate your general state of health?" rated on a 5-point Likert scale at 90 minutes post-injection
Facial appearence
Photos were taken under standardised conditions before and after injection
Full Information
NCT ID
NCT03551184
First Posted
May 29, 2018
Last Updated
May 29, 2018
Sponsor
Karolinska Institutet
Collaborators
University of California, San Francisco, The Swedish Society of Medicine, Swedish Heart Lung Foundation, The Swedish Research Council, Swedish Council for Working Life and Social Research, Stockholm University
1. Study Identification
Unique Protocol Identification Number
NCT03551184
Brief Title
Inflammation and Brain Function - Main Study
Official Title
Inflammation Och hjärnfunktion - Huvudstudie
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
October 2010 (Actual)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
March 2011 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Karolinska Institutet
Collaborators
University of California, San Francisco, The Swedish Society of Medicine, Swedish Heart Lung Foundation, The Swedish Research Council, Swedish Council for Working Life and Social Research, Stockholm University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this randomized double blind study, 52 healthy participants were injected with either 0.6 ng/kg body weight or placebo to test if changes in pain sensitivity is associated with change in neural activity using BOLD MR scanning.
Detailed Description
52 healthy participants were included in this randomized double blind study. Participants were injected once, and randomized to injection with with the active component or placebo. Participants were recruited by advertising and screened through questionnaires and a health examination by a physician. They were asked not to engage in strenuous physical activities, sleep regular hours and refrain from alcohol the day before the experiment. If the participants felt ill, e.g. coming down with a cold, they were instructed to call and were rescheduled for a later appointment. C-reactive protein (CRP) was assessed to exclude participants having an ongoing infection on the experimental day. Pregnancy was also an exclusion criteria and a pregnancy test was administered for all female participants on arrival. Pain sensitivity measures were tested at baseline and at peak inflammatory response 1-2 hours after injection. Both deep and cutaneous pain at threshold and suprathreshold noxious levels were tested. Heat- and cold (cutaneous) pain sensitivity was assessed for threshold stimuli and intense noxious stimuli, as well as pressure (deep) pain thresholds and CPM (descending pain inhibition). These tests were conducted while the participants were in the MR-scanner to investigate neural correlates to change in pain sensitivity. Subjects filled out questionnaires at baseline, 90 minutes, 3.5 and 5 hours after injection.
The study and the procedures used in the study are described in detail here: https://openarchive.ki.se/xmlui/bitstream/handle/10616/44650/Thesis_Bianka_Karshikoff.pdf?sequence=8&isAllowed=y
The following papers using data from this study is published:
Lindstedt F, Karshikoff B, Schalling M, Olgart Hoglund C, Ingvar M, Lekander M & Kosek E. Serotonin-1A Receptor Polymorphism (rs6295) Associated with Thermal Pain Perception. PLOS ONE. 2012;7(8):e43221. Epub 2012/09/07.
Karshikoff B, Jensen KB, Kosek E, Kalpouzos G, Soop A, Ingvar M, Olgart Höglund C, Lekander M, Axelsson J. Why sickness hurts: A central mechanism for pain induced by peripheral inflammation. Brain, Behavior, and Immunity 2016 Oct;57:38-46.
Lekander M, Karshikoff B, Johansson E, Soop A, Fransson P, Lundström J N, Andreasson A, Ingvar M, Petrovic P, Axelsson J/Nilsonne G. Intrinsic functional connectivity of insular cortex and symptoms of sickness during acute experimental inflammation. Brain, Behavior, and Immunity 2016 Aug;56:34-41.
Andreasson A, Wicksell RK, Lodin K, Karshikoff B, Axelsson J, Lekander M. A Global Measure of Sickness Behavior: Development of the Sickness Questionnaire (SicknessQ). Journal of Health Psychology. 2016 Jul 24.
Karshikoff B, Lekander M, Soop A, Lindstedt F, Ingvar M Kosek E, Olgart Höglund C, & Axelsson J. Modality and sex differences in pain sensitivity during human endotoxemia. Brain, Behavior, and Immunity. 2015 May;46:35-43
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickness Behavior
Keywords
Sickness behavior, Endotoxin, Lipopolysaccharide, Psychoneuroimmunology
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
52 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Endotoxin
Arm Type
Active Comparator
Arm Description
Endotoxin 0.6 ng/kg body weight injection
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Saline injection
Intervention Type
Biological
Intervention Name(s)
Endotoxin
Other Intervention Name(s)
LPS, Lipopolysaccharide
Intervention Description
Endotoxin at 0.6 ng/kg of body weight administered intravenously (Escherichia Coli, Lot nr G3E0609, United States Pharmacopeia Rockville, MD)
Intervention Type
Biological
Intervention Name(s)
Placebo
Intervention Description
Saline administered intravenously
Primary Outcome Measure Information:
Title
Pain sensitivity (cutaneous and deep)
Description
Both deep and cutaneous pain at threshold and suprathreshold noxious levels. Heat- and cold (cutaneous) pain sensitivity was assessed for threshold stimuli and intense noxious stimuli, as well as pressure (deep) pain thresholds and CPM (descending pain inhibition).
Time Frame
7.5 hours
Title
Brain function
Description
BOLD activity from MR scans
Functional connectivity of the insular cortex during acute inflammation, in relation to symptoms of sickness.
Changes in central pain mechanism during acute inflammation, assessed as activity in the insula and areas of the descending pain inhibitory pathways in the brain.
Changes in brain function during an emotional task with an interoceptive component during acute inflammation.
Time Frame
7.5 hours
Secondary Outcome Measure Information:
Title
Self-rated health
Description
"How is your health right now?" rated on a 7 point Likert scale at baseline, after 90 minutes and after 4.5 hours.
"How do you rate your general state of health?" rated on a 5-point Likert scale at 90 minutes post-injection
Time Frame
4.5 hours
Title
Facial appearence
Description
Photos were taken under standardised conditions before and after injection
Time Frame
2 h
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy subjects
Exclusion Criteria:
Diagnosed physiological or psychiatric disease
Needle anxiety or blood phobia
Regular medication (excluding contraceptive pill)
Infection in the last two weeks
Pregnancy or breastfeeding
Smoking
Excessive alcohol use
Body mass index in the range of obesity (>30 kg/m2) or underweight (<18.5 kg/m2)
Invisible veins in the antecubital area of the arms
Known or risk of metal inserted in body
Claustrophobic tendensies
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Inflammation and Brain Function - Main Study
We'll reach out to this number within 24 hrs